


PHARMACEUTICAL 2020



Advaxis Inc. Rank 136 of 362





PHARMACEUTICAL 2020



Advaxis Inc. Rank 136 of 362

The relative strengths and weaknesses of Advaxis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Advaxis Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 226% points. The greatest weakness of Advaxis Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 122% points.

The company's Economic Capital Ratio, given in the ranking table, is -94%, being 209% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	36,149
Cost of Goods Sold	0
Intangible Assets	4,575
Liabilities, Current	4,521
Liabilities, Non-Current	1,205
Other Assets	183
Other Compr. Net Income	0
Other Expenses	1,657
Other Liabilities	0
Other Net Income	2,582
Property and Equipment	4,350
Research and Development	26,677
Revenues	21,319
Selling, General and Administrative Expense	12,179

Output Variable	Value in 1000 USD
Assets	45,257
Liabilities	5,726
Expenses	40,513
Stockholders Equity	39,531
Net Income	-16,612
Comprehensive Net Income	-16,612
Economic Capital Ratio	-94%